Table 1. Open in new tab Study...

Donor	Age, y	Time Since HIV Diagnosis, y	Pre-ART	Under Ongoing ART
1	57	26	<200	NA	26	1378	964	1.43	EVG/c + TAF + FTC
2	56	15	119	111 000	15	470	470	1	BIC + TAF + FTC
3	41	12	302	27 713	12	936	347	2.7	BIC + TAF + FTC
4	42	19	11	NA	19	1230	572	2.15	RAL + TDF + FTC
5	62	14	281	53 000	14	1193	1023	1.17	DOL + RPV
6	73	10.8	137	234 000	10.8	410	950	0.43	RPV + TAF + FTC
7	45	20	32	580 000	20	874	650	1.34	BIC + TAF + FTC
8	62	10.4	13	1 300 000	10.4	852	1918	0.44	DOL + 3TC
9	41	6	390	1800	6	738	539	1.37	DOL + 3TC
10	55	6	359	2000	6	909	464	1.96	EVG/c + TAF + FTC
11	51	13.7	195	237 000	13.7	784	669	1.17	NVP + TDF + FTC
12	33	11.5	270	69 000	11.5	734	490	1,5	RPV + TAF + FTC
13	50	6	514	21 000	6	926	881	1.05	BIC + TAF + FTC
14	33	1.6	521	73 000	1.6	1141	680	1.35	DOR + TDF + 3TC
15	30	4.4	607	14 800	4.4	2003	668	3	DOL + 3TC
16	63	18.8	43	236 000	18.8	691	1072	0.64	BIC + TAF + FTC
17	29	4.2	368	3754	4.2	702	463	1.52	RPV + TAF + FTC
18	56	23.4	40	30 500	23.4	689	638	1.08	DOL + 3TC
19	46	7.2	338	197 000	7.2	1325	1263	1.05	DOL + ABC + 3TC
20	34	10	300	NA	10	880	730	1.21	NVP + TDF + FTC

Donor

Age, y

Time Since HIV Diagnosis, y

Pre-ART

Under Ongoing ART

Total CD4 Nadir, Cells/µL

HIV RNA^a, Copies/mL

Time on ART, y

Total CD4 Count^b, Cells/µL

Total CD8 Count^b, Cells/µL

CD4/CD8 T-Cell Ratio^b

ART Regimen

<200

1378

964

1.43

EVG/c + TAF + FTC

119

111 000

470

BIC + TAF + FTC

302

27 713

936

347

2.7

BIC + TAF + FTC

1230

572

2.15

RAL + TDF + FTC

281

53 000

1193

1023

1.17

DOL + RPV

10.8

137

234 000

10.8

410

950

0.43

RPV + TAF + FTC

580 000

874

650

1.34

BIC + TAF + FTC

10.4

1 300 000

10.4

852

1918

0.44

DOL + 3TC

390

1800

738

539

1.37

DOL + 3TC

359

2000

909

464

1.96

EVG/c + TAF + FTC

13.7

195

237 000

13.7

784

669

1.17

NVP + TDF + FTC

11.5

270

69 000

11.5

734

490

1,5

RPV + TAF + FTC

514

21 000

926

881

1.05

BIC + TAF + FTC

1.6

521

73 000

1.6

1141

680

1.35

DOR + TDF + 3TC

4.4

607

14 800

4.4

2003

668

DOL + 3TC

18.8

236 000

18.8

691

1072

0.64

BIC + TAF + FTC

4.2

368

3754

4.2

702

463

1.52

RPV + TAF + FTC

23.4

30 500

23.4

689

638

1.08

DOL + 3TC

7.2

338

197 000

7.2

1325

1263

1.05

DOL + ABC + 3TC

300

880

730

1.21

NVP + TDF + FTC

Donor	Age, y	Time Since HIV Diagnosis, y	Pre-ART	Under Ongoing ART
1	57	26	<200	NA	26	1378	964	1.43	EVG/c + TAF + FTC
2	56	15	119	111 000	15	470	470	1	BIC + TAF + FTC
3	41	12	302	27 713	12	936	347	2.7	BIC + TAF + FTC
4	42	19	11	NA	19	1230	572	2.15	RAL + TDF + FTC
5	62	14	281	53 000	14	1193	1023	1.17	DOL + RPV
6	73	10.8	137	234 000	10.8	410	950	0.43	RPV + TAF + FTC
7	45	20	32	580 000	20	874	650	1.34	BIC + TAF + FTC
8	62	10.4	13	1 300 000	10.4	852	1918	0.44	DOL + 3TC
9	41	6	390	1800	6	738	539	1.37	DOL + 3TC
10	55	6	359	2000	6	909	464	1.96	EVG/c + TAF + FTC
11	51	13.7	195	237 000	13.7	784	669	1.17	NVP + TDF + FTC
12	33	11.5	270	69 000	11.5	734	490	1,5	RPV + TAF + FTC
13	50	6	514	21 000	6	926	881	1.05	BIC + TAF + FTC
14	33	1.6	521	73 000	1.6	1141	680	1.35	DOR + TDF + 3TC
15	30	4.4	607	14 800	4.4	2003	668	3	DOL + 3TC
16	63	18.8	43	236 000	18.8	691	1072	0.64	BIC + TAF + FTC
17	29	4.2	368	3754	4.2	702	463	1.52	RPV + TAF + FTC
18	56	23.4	40	30 500	23.4	689	638	1.08	DOL + 3TC
19	46	7.2	338	197 000	7.2	1325	1263	1.05	DOL + ABC + 3TC
20	34	10	300	NA	10	880	730	1.21	NVP + TDF + FTC

Table 1.

Open in new tab

Study Participant Characteristics

Donor	Age, y	Time Since HIV Diagnosis, y	Pre-ART		Under Ongoing ART
Donor	Age, y	Time Since HIV Diagnosis, y	Total CD4 Nadir, Cells/µL	HIV RNA^a, Copies/mL	Time on ART, y	Total CD4 Count^b, Cells/µL	Total CD8 Count^b, Cells/µL	CD4/CD8 T-Cell Ratio^b	ART Regimen
1	57	26	<200	NA	26	1378	964	1.43	EVG/c + TAF + FTC
2	56	15	119	111 000	15	470	470	1	BIC + TAF + FTC
3	41	12	302	27 713	12	936	347	2.7	BIC + TAF + FTC
4	42	19	11	NA	19	1230	572	2.15	RAL + TDF + FTC
5	62	14	281	53 000	14	1193	1023	1.17	DOL + RPV
6	73	10.8	137	234 000	10.8	410	950	0.43	RPV + TAF + FTC
7	45	20	32	580 000	20	874	650	1.34	BIC + TAF + FTC
8	62	10.4	13	1 300 000	10.4	852	1918	0.44	DOL + 3TC
9	41	6	390	1800	6	738	539	1.37	DOL + 3TC
10	55	6	359	2000	6	909	464	1.96	EVG/c + TAF + FTC
11	51	13.7	195	237 000	13.7	784	669	1.17	NVP + TDF + FTC
12	33	11.5	270	69 000	11.5	734	490	1,5	RPV + TAF + FTC
13	50	6	514	21 000	6	926	881	1.05	BIC + TAF + FTC
14	33	1.6	521	73 000	1.6	1141	680	1.35	DOR + TDF + 3TC
15	30	4.4	607	14 800	4.4	2003	668	3	DOL + 3TC
16	63	18.8	43	236 000	18.8	691	1072	0.64	BIC + TAF + FTC
17	29	4.2	368	3754	4.2	702	463	1.52	RPV + TAF + FTC
18	56	23.4	40	30 500	23.4	689	638	1.08	DOL + 3TC
19	46	7.2	338	197 000	7.2	1325	1263	1.05	DOL + ABC + 3TC
20	34	10	300	NA	10	880	730	1.21	NVP + TDF + FTC

Donor	Age, y	Time Since HIV Diagnosis, y	Pre-ART		Under Ongoing ART
Donor	Age, y	Time Since HIV Diagnosis, y	Total CD4 Nadir, Cells/µL	HIV RNA^a, Copies/mL	Time on ART, y	Total CD4 Count^b, Cells/µL	Total CD8 Count^b, Cells/µL	CD4/CD8 T-Cell Ratio^b	ART Regimen
1	57	26	<200	NA	26	1378	964	1.43	EVG/c + TAF + FTC
2	56	15	119	111 000	15	470	470	1	BIC + TAF + FTC
3	41	12	302	27 713	12	936	347	2.7	BIC + TAF + FTC
4	42	19	11	NA	19	1230	572	2.15	RAL + TDF + FTC
5	62	14	281	53 000	14	1193	1023	1.17	DOL + RPV
6	73	10.8	137	234 000	10.8	410	950	0.43	RPV + TAF + FTC
7	45	20	32	580 000	20	874	650	1.34	BIC + TAF + FTC
8	62	10.4	13	1 300 000	10.4	852	1918	0.44	DOL + 3TC
9	41	6	390	1800	6	738	539	1.37	DOL + 3TC
10	55	6	359	2000	6	909	464	1.96	EVG/c + TAF + FTC
11	51	13.7	195	237 000	13.7	784	669	1.17	NVP + TDF + FTC
12	33	11.5	270	69 000	11.5	734	490	1,5	RPV + TAF + FTC
13	50	6	514	21 000	6	926	881	1.05	BIC + TAF + FTC
14	33	1.6	521	73 000	1.6	1141	680	1.35	DOR + TDF + 3TC
15	30	4.4	607	14 800	4.4	2003	668	3	DOL + 3TC
16	63	18.8	43	236 000	18.8	691	1072	0.64	BIC + TAF + FTC
17	29	4.2	368	3754	4.2	702	463	1.52	RPV + TAF + FTC
18	56	23.4	40	30 500	23.4	689	638	1.08	DOL + 3TC
19	46	7.2	338	197 000	7.2	1325	1263	1.05	DOL + ABC + 3TC
20	34	10	300	NA	10	880	730	1.21	NVP + TDF + FTC

Abbreviations: 3TC, lamivudine; ABC, abacavir; ART, antiretroviral therapy; BIC, bictegravir; DOL, dolutegravir; DOR, doravirine; EVG/c, elvitegravir/cobicistat; FTC, emtricitabine; HIV, human immunodeficiency virus; NA, not available; NVP, nevirapine; RAL, raltegravir; RPV, rilpivirine; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate.

^aMeasured before start of ART.

^bMeasured at most recent blood withdrawal.

This Feature Is Available To Subscribers Only